<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714229</url>
  </required_header>
  <id_info>
    <org_study_id>EuVCT_MCV101</org_study_id>
    <nct_id>NCT04714229</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old</brief_title>
  <official_title>A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135 and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuBiologics Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuBiologics Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a&#xD;
      single dose administration of Meningococcal (Group A, C, W-135, and Y)-CRM197 Conjugate&#xD;
      vaccine&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited adverse events</measure>
    <time_frame>within 7 days post vaccination</time_frame>
    <description>local and systemic AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited adverse events</measure>
    <time_frame>within 28 days post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>within 180 days post vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Infection, Meningococcal</condition>
  <arm_group>
    <arm_group_label>EuMCV4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults received 0.5mL single intramuscular dose on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menveo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adults received 0.5mL single intramuscular dose on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine</intervention_name>
    <description>0.5mL single intramuscular dose on Day 0</description>
    <arm_group_label>EuMCV4</arm_group_label>
    <other_name>EuMCV4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine</intervention_name>
    <description>0.5mL single intramuscular dose on Day 0</description>
    <arm_group_label>Menveo</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects 19 to 55 years of age&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Available for all visits and telephone calls scheduled for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or suspected disease caused by N. meningitidis&#xD;
&#xD;
          -  Household and/or intimate exposure to an individual with culture-proven N.&#xD;
             meinigitidis infection within 60 days prior to screening&#xD;
&#xD;
          -  Serious acute, chronic or progressive disease as determined by investigator&#xD;
&#xD;
          -  History of alcohol or substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YJ Lee</last_name>
    <role>Study Director</role>
    <affiliation>EuBiologics Co.,Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

